feat(veridian): Veridian BioSciences Enterprise AI Strategy & Implementation Plan 2026-2030

Sector-specific Fortune 500 deliverable for Biopharmaceutical R&D:

Company: Veridian BioSciences, $28.4B revenue, #180 Fortune 500, 62K employees
Sector: AI-Driven Drug Discovery & Clinical Trial Optimization

Strategic Reasoning (transparent pre-assessment):
- Bottleneck: 4.8yr target-to-IND, 14 incompatible LIMS, 72% manual submissions
- EU AI Act Art. 14 vs zero-human-intervention → Supervised Autonomy resolution
- $380.7M gross gains - $73.3M risk costs = $307.4M/yr net value capture
- $842M 5-year NPV, 4.2x ROI, 26-month payback on $458M investment
- 6 data dependencies mapped to roadmap gates (LIMS = critical path)

Report Sections:
1. Executive Summary with derived Net Value metrics
2. Technology Roadmap (2026-2030): Data Foundation → Molecular AI → Clinical AI →
   Manufacturing Intelligence → Project Depths (full supervised autonomy)
3. Project Depths Risk Case Study: 7 risk categories with dual technical/governance
   mitigations (circuit breakers, ensemble UQ, Byzantine FL, blast radius governors,
   SHAP/GradCAM interpretability, DP-SGD, Fairlearn)
4. Deployment Framework: Hybrid edge-cloud (<20ms mfg, GDPR sovereignty, on-prem IP),
   6-phase Year 1 kickoff ($36M, 42 new hires, peak 35 FTE)
5. Financial Deep-Dive: 5-year cost model ($379.5M), benefits ($881.6M),
   sensitivity analysis (5 variables), value driver breakdown (Canvas pie chart)

14 KPIs: OEE 78→88%, carbon -28%, screen failure 31→19%, R&D cycle 4.8→2.9yr
REST APIs: /api/veridian, /api/veridian/financials, /api/veridian/risks,
  /api/veridian/roadmap, /api/veridian/kpis
Dashboard: /veridian-biosciences.html — 3 Canvas charts, TOC sidebar, responsive, A4 print
Zero console errors on all pages

Author: OneFineStarstuff